Oncolytics Biotech Inc T.ONC

ASCO

[lonc17]

First glance.. the six month PFS rate is very eye-catching. 

Numbers look good, favouring Pelareorep and providing further support for IND213. 

Slight concern about toxicity, which we have not had trouble with before. 

I'm expecting the SP to pop up nicely tomorrow morning, but ONC's SP has always responded in unexpected ways. 

The data fully support moving to a P3, IMO.

https://meetings.asco.org/abstracts-presentations/220680

[westcoast1000]

Thanks to Ionc for finding the abstract and posting it. I am not conversant enough with the findings to draw any conclusions. They seem good based on simply looking at them compared to cohort 1 the standard of care.  But bear in mind that these these are metastatic BC cases, of which over 80% had visceral disease. meaning liver, stomach etc metastaces. That is serious illness. 

[Lesalpes29]

Good point Westcoast. The patients treated were not in good shape to say the least. Very good results. GL longs,

[Noteable]

Both the pelareorep as a single agent and pelareorep in combination with an immune checkpoint inhibitor results in heavily pre-treated patients were extraordinary given that neither agent have been used to treat breast cancer. So good that the Bracelet-1 trial resuts earned an ASCO oral presentation on June 03, 2023.

[13X2413]

I hope you're right about a possible pop. At first glance, the toxicity concerns jump out at you. I hope that issue isn't a concern for the investment community.  I'm far from an expert so take my blurb with a grain of salt. 

[Noteable]

Of particular significance is the confirmation that the addition of pelareorep to paciltaxel is an active regimen with a high 6-month PFS, and proving pelareorep's single agent activity in breast cancer patients who were heavily pre-treated prior to entering the trial. The trial results also showed that pelareorep's single agent activity significantly surpassed the 6 month PFS